Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | SLC26A6 | Q9BXS9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31285809 | 0.83 | IDO1 (0.47) | IDO1ALDH1A1MAPTLMNAHTT | |
| SCHEMBL4782884 | 0.83 | IDO1 (0.47) | IDO1ALDH1A1MAPTLMNAHTT | |
| SCHEMBL4733727 | 0.69 | MAPT (0.55) | ALDH1A1MAPTLMNAHTTNPSR1 | |
| SCHEMBL12426299 | 0.68 | MAPT (0.45) | ALDH1A1MAPTLMNANPSR1SMN1; SMN2 | |
| SCHEMBL31714647 | 0.67 | — | — | |
| SCHEMBL8096184 | 0.67 | ACHE (0.31) | — | |
| SCHEMBL17498385 | 0.66 | IDO1 (0.59) | IDO1KDM4EHPGD | |
| SCHEMBL31715201 | 0.65 | EGFR (0.35) | — | |
| SCHEMBL1703281 | 0.64 | LMNA (0.45) | IDO1ALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL29525602 | 0.64 | IDO1 (1.00) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2025-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, IRF3 | IDO1 1299/4885ALDH1A1 3515/4885MAPT 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.